Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nkarta Inc (NQ: NKTX )

1.620 +0.010 (+0.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 274,500
Open 1.590
Bid (Size) 1.570 (2)
Ask (Size) 1.750 (1)
Prev. Close 1.610
Today's Range 1.550 - 1.630
52wk Range 1.550 - 14.57
Shares Outstanding 48,934,928
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
The Latest Analyst Ratings for Nkarta
Via Benzinga

Performance

YTD
-73.13%
-73.13%
1 Month
-7.95%
-7.95%
3 Month
-64.24%
-64.24%
6 Month
-53.58%
-53.58%
1 Year
-86.80%
-86.80%

More News

Read More
Analyst Expectations for Nkarta's Future
Via Benzinga
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
3 Hidden Penny Stocks That Could Turn $100 into $10,000
Via InvestorPlace
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
NKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development Timeline
Via Benzinga
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nkarta's Updated Data From Leukemia Study Fails To Cheer Investors
Via Benzinga
Why Shares of Nkarta Are Slumping Tuesday
Via The Motley Fool
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
From Nkarta, Inc.
Via GlobeNewswire
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
From Nkarta, Inc.
Via GlobeNewswire
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
7 Stocks With Promising Upside Potential for 100% Returns
Via InvestorPlace
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
From Nkarta, Inc.
Via GlobeNewswire
3 Biotech Stocks to Watch for Potential Breakthroughs
Via InvestorPlace
NVIDIA To Rally Around 19%? Here Are 10 Other Analyst Forecasts For Friday
Via Benzinga
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Via TheNewswire.com
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.